AveXis — Corporate Update (October 2016)
21 slides from AveXis's corporate update, Oct 11, 2016
Slide 1: Forward-Looking Statements
2 Forward-Looking Statements This presentation contains forward-looking statements, including: statements about: the timing, progress and results of preclinical studies and clinical trials for AVXS-101, including statements regarding the timing of initiation and completion of studies or trials and r
Slide 2: Overview of SMA
Overview of SMA 3 SMA is a devastating orphan disease – with no current FDA-approved treatments – that results in motor neuron loss and progressive weakness; it is the most common genetic cause of infant death Incidence: ~1 in 10,000 live births Caused by reduced SMN (survival motor neuron) protein
Slide 3: SMA Types: A Devastating Disease
SMA Types: A Devastating Disease 4 TYPE 1 TYPE 2 TYPE 3 TYPE 4 SMN2 Copy Number Two Three or Four Three or Four Four to Eight Onset Before 6 Months 6-18 Months Early childhood to early adulthood (juvenile) Adulthood (20s-30s) usually after 30 Incidence per Live Birth Approximately 60% Approximately
Slide 4: Natural History of SMA Type 1
Natural History of SMA Type 1 “floppy baby” syndrome muscle weakness (legs more than arms) poor head control belly breathing bulbar muscle weakness (weak cry, difficulty swallowing, aspiration) will never sit unsupported loss of motor function: NeuroNEXT -- CHOP INTEND decrease of 10.5 points/yr. PN
Slide 5: AVXS-101 Targets the Primary SMN Gene
AVXS-101 Targets the Primary SMN Gene 6 NORMAL INDIVIDUAL SMA-AFFLICTED INDIVIDUAL SMA-AFFLICTED INDIVIDUAL TREATED WITH AVXS-101 SMN Genes SMN Protein SMN1 Primary SMN2 Back up SMN Genes SMN Protein SMN1 SMN2 Back up SMN Genes SMN Protein SMN1 SMN2 Back up AVXS-101 Primary Functional SMN Protein No
Slide 6: Our Solution: AVXS-101 An Innovative Treatment Approach for SMA
Our Solution: AVXS-101 An Innovative Treatment Approach for SMA 7 scAAV ITR Continuous Promoter Human SMN Transgene scAAV ITR KEY COMPONENTS PURPOSE Recombinant AAV9 Capsid Shell Ability to deliver across the blood brain barrier (BBB) and into the spinal cord - Avoids the need for intrathecal delive
Slide 7: Phase 1 Trial Design
Phase 1 Trial Design 8 TRIAL OVERVIEW Route of Administration One-time intravenous infusion through peripheral limb vein Prednisolone 1 mg/kg 1 day Pre-GT Trial Design Open-label, dose-escalation Principal Investigator Jerry R. Mendell, M.D. TRIAL OVERVIEW Study Site OBJECTIVES Primary Safety and To
Slide 8: Event-Free Survival Data – Ongoing Phase 1 Trial
Event-Free Survival Data – Ongoing Phase 1 Trial * A month is defined as 30 days Cohort 1 6.7E13 vg/kg Cohort 2 2.0E14 vg/kg PNCR (Finkel) 2014 Natural History Study: 75% event-free 50% event-free 25% event-free 8% event-free 9 SURVIVAL DATA 9/9 reached 20 mo. event-free (8% PNCR) 12/12 reached 13.6
Slide 9: CHOP INTEND vs. Age
CHOP INTEND vs. Age Early intervention and dose appear to affect response 6 10 COHORT 1 (n=3) Baseline Age (months): 5.9 [median], 6.3 [mean] Current Age* (months): 30.8 [median], 30.3 [mean] Mean CHOP INTEND Increase: 9.0 points COHORT 2 (n=12) Baseline Age (months): 3.1 [median], 3.4 [mean] Curren
Slide 10: Safety Data – Ongoing Phase 1 Trial
Safety Data – Ongoing Phase 1 Trial SAFETY AND TOLERABILITY OBSERVATIONS No new treatment-related SAEs or AEs observed As previously reported, a total of 5 treatment-related AEs in 4 patients have been observed to date Treatment-related SAEs and AEs were clinically asymptomatic elevated liver functi
Slide 11: Children with SMA Type 1 Never Sit Unassisted
Children with SMA Type 1 Never Sit Unassisted 12 Disease Characteristics Disease onset <6 months Hypotonia and weakness Bulbar muscle weakness Difficulty breathing and swallowing Inexorable progression to nutritional failure Inexorable progression to respiratory failure Developmental Milestone Progn
Slide 12: Motor Milestone Achievement in Proposed Therapeutic Dose (Interim Data)
Motor Milestone Achievement in Proposed Therapeutic Dose (Interim Data) 13 Cohort 2 2.0e14 vg/kg Age at GT (mos) Motor Milestone Achievement Brings hand to mouth Head control Rolls over (partial) Rolls over (complete) Sitting with assistance Sitting unassisted E.04 6 E.05 4 E.06 2 E.07 4 E.08 8 E.09
Slide 13: Two-thirds of Patients in Cohort are Sitting Unassisted
Two-thirds of Patients in Cohort 2 are Sitting Unassisted Inability to Sit is the Hallmark Motor Milestone of SMA Type 1 E.06 E.12 E.09 E.05 E.10 E.07 E.11 E.04
Slide 14: Patients with CHOP INTEND > 40
Patients with CHOP INTEND > 40 15 0 10 20 30 40 50 60 0 3 6 9 12 15 18 21 24 27 CHOP INTEND Scores Age (months) 1 month = 30 days
Slide 15: Patients with CHOP INTEND > 40 (E.11)
Patients with CHOP INTEND > 50 16 E.11 sitting unassisted and standing with support were confirmed with video evidence after September 15, 2016 0 10 20 30 40 50 60 0 3 6 9 12 15 18 21 24 27 CHOP INTEND Scores Age (months) 1 month = 30 days
Slide 16: Patients with CHOP INTEND > 40 (E.10)
Patients with CHOP INTEND > 60 17 E.10 walking independently was confirmed with video evidence after September 15, 2016 0 10 20 30 40 50 60 0 3 6 9 12 15 18 21 24 27 CHOP INTEND Scores Age (months) 1 month = 30 days
Slide 17: Summary: Ongoing Phase 1 Data
Summary: Ongoing Phase 1 Data 18 AVXS-101 appears to have a favorable safety profile and appears to be generally well tolerated A total 118 AEs (34 SAEs and 84 non-serious AEs) have been reported No additional treatment-related AEs have been observed beyond the previously reported five elevated LFEs
Slide 18: Clinical Development Milestones
Clinical Development Milestones 19 2016 2H 2016: Provide update on FDA Type B meeting Q1 2017: 13.6 months of data for all patients in the SMA Type 1 Phase 1 trial 2H 2016: Initiate Phase 1 safety and dosing study in SMA Type 2 via intrathecal (IT) delivery 1H 2017: Initiate SMA Type 1 pivotal trial
Slide 19: Question and Answer Session
Question and Answer Session October 10, 2016
Slide 20: Question and Answer Session
Question and Answer Session aveis October 10, 2016
Slide 21: Thank You
Thank You aveRis